Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Linda Dayer-Berenson & Mary Finckenor. (2014) Expanded Colesevelam Administration Options With Oral Suspension Formulation for Patients With Diabetes and Hypercholesterolemia. Postgraduate Medicine 126:3, pages 126-134.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Michel Farnier. (2011) Safety review of combination drugs for hyperlipidemia. Expert Opinion on Drug Safety 10:3, pages 363-371.
Read now
Read now
Aris P Agouridis, Theodosios D Filippatos, Vasilios Tsimihodimos & Moses S Elisaf. (2011) Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Review of Cardiovascular Therapy 9:3, pages 355-366.
Read now
Read now
Nkechinyere Ijioma & Jennifer G Robinson. (2011) Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy 9:2, pages 131-145.
Read now
Read now
Adie Viljoen & Anthony S Wierzbicki. (2010) Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. Expert Review of Endocrinology & Metabolism 5:6, pages 825-834.
Read now
Read now
Alberico L. Catapano. (2009) Perspectives on low-density lipoprotein cholesterol goal achievement. Current Medical Research and Opinion 25:2, pages 431-447.
Read now
Read now
Padmini Manghat & Anthony Wierzbicki. (2008) Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidology 3:3, pages 237-255.
Read now
Read now
Roeland Huijgen, Maud N Vissers, Joep C Defesche, Peter J Lansberg, John JP Kastelein & Barbara A Hutten. (2008) Familial hypercholesterolemia: current treatment and advances in management. Expert Review of Cardiovascular Therapy 6:4, pages 567-581.
Read now
Read now
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, pages 995-1009.
Read now
Read now
Harold Bays & Peter H Jones. (2007) Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vascular Health and Risk Management 3:5, pages 733-742.
Read now
Read now
Michael H Davidson. (2007) The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opinion on Pharmacotherapy 8:15, pages 2569-2578.
Read now
Read now
Articles from other publishers (36)
Harold Edward Bays. 2023. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
705
734
.
E. E. Buyko, V. V. Ivanov, O. A. Kaidash, O. Yu. Rybalkina, E. A. Kiseleva, S. V. Krivoshchekov, T. L. Kiseleva, A. M. Guriev & M. V. Belousov. (2022) Hypolipidemic activity of the polysaccharide L-rhamnopyranosyl-6-O-methyl-galacturonan in combined administration with HMG-CoA reductase and cholesterol absorption inhibitors. Drug development & registration 11:3, pages 57-63.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
133
198
.
Natalie C. Ward & Gerald F. Watts. 2021. Therapeutic Lipidology. Therapeutic Lipidology
615
636
.
Josefin Soppert, Michael Lehrke, Nikolaus Marx, Joachim Jankowski & Heidi Noels. (2020) Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews 159, pages 4-33.
Crossref
Crossref
Cori Russell, Samip Sheth & Douglas Jacoby. (2018) A Clinical Guide to Combination Lipid-Lowering Therapy. Current Atherosclerosis Reports 20:4.
Crossref
Crossref
Yoshihide Yamanashi, Tappei Takada & Hiroshi Suzuki. 2017. Bile Acids in Gastroenterology. Bile Acids in Gastroenterology
61
90
.
Handrean Soran, Jonathan D. Schofield, Safwaan Adam & Paul N. Durrington. (2016) Diabetic dyslipidaemia. Current Opinion in Lipidology 27:4, pages 313-322.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, Carl E. Orringer, W. Virgil Brown & Terry A. Jacobson. (2016) National Lipid Association Annual Summary of Clinical Lipidology 2016. Journal of Clinical Lipidology 10:1, pages S1-S43.
Crossref
Crossref
Peter P. Toth, Dragana Nikolic, Manfredi Rizz, Jacek Rysz & Maciej Banach. 2015. Combination Therapy In Dyslipidemia. Combination Therapy In Dyslipidemia
1
10
.
Stanley J. Goldberg. 2015. Lipid Management. Lipid Management
201
231
.
Harold E. Bays, Peter H. Jones, W. Virgil Brown & Terry A. Jacobson. (2014) National Lipid Association Annual Summary of Clinical Lipidology 2015. Journal of Clinical Lipidology 8:6, pages S1-S36.
Crossref
Crossref
R Tompkins, A Schwartzbard, E Gianos, E Fisher & H Weintraub. (2014) A Current Approach to Statin Intolerance. Clinical Pharmacology & Therapeutics 96:1, pages 74-80.
Crossref
Crossref
Harold Bays. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
415
433
.
Michael R. Jones & Oliseyenum M. Nwose. (2013) Role of Colesevelam in Combination Lipid-Lowering Therapy. American Journal of Cardiovascular Drugs 13:5, pages 315-323.
Crossref
Crossref
Ovidio Muñiz Grijalvo & Jose Villar Ortiz. (2013) Tratamiento combinado: pautas, indicaciones y perfil de seguridad. Clínica e Investigación en Arteriosclerosis 25:3, pages 140-145.
Crossref
Crossref
Patrick Couture & Benoît Lamarche. (2013) Ezetimibe and bile acid sequestrants. Current Opinion in Lipidology 24:3, pages 227-232.
Crossref
Crossref
Franco Scaldaferri, Marco Pizzoferrato, Francesca Romana Ponziani, Giovanni Gasbarrini & Antonio Gasbarrini. (2011) Use and indications of cholestyramine and bile acid sequestrants. Internal and Emergency Medicine 8:3, pages 205-210.
Crossref
Crossref
Jennifer Santee, Cameron Lindsey & Heather Pace. (2012) Relative Efficacy of Antilipemic Agents in Non–High-Density Lipoprotein Cholesterol Reduction. Journal of Pharmacy Practice 25:4, pages 447-456.
Crossref
Crossref
Carolien Out, Albert K. Groen & Gemma Brufau. (2012) Bile acid sequestrants. Current Opinion in Lipidology 23:1, pages 43-55.
Crossref
Crossref
Luigi Brunetti & R. Keith Campbell. (2011) Clinical Efficacy of Colesevelam in Type 2 Diabetes Mellitus. Journal of Pharmacy Practice 24:4, pages 417-425.
Crossref
Crossref
Yehuda Handelsman & Paul S. Jellinger. (2011) Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 13:8, pages 613-620.
Crossref
Crossref
Clay F. Semenkovich, Anne C. Goldberg & Ira J. Goldberg. 2011. Williams Textbook of Endocrinology. Williams Textbook of Endocrinology
1633
1674
.
Luigi Brunetti & Evelyn R Hermes-DeSantis. (2010) The Role of Colesevelam Hydrochloride in Hypercholesterolemia and Type 2 Diabetes Mellitus. Annals of Pharmacotherapy 44:7-8, pages 1196-1206.
Crossref
Crossref
Karen S. Brown, Ingrid C. Armstrong, Antonia Wang, Joseph R. Walker, Robert J. Noveck, Dennis Swearingen, Mark Allison, James C. Kissling, James Kisicki & Daniel E. Salazar. (2013) Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide. The Journal of Clinical Pharmacology 50:5, pages 554-565.
Crossref
Crossref
Todd C. Rideout, Scott V. Harding, Christopher P.F. Marinangeli & Peter J.H. Jones. (2010) Combination drug–diet therapies for dyslipidemia. Translational Research 155:5, pages 220-227.
Crossref
Crossref
Roeland Huijgen, Evertine J. Abbink, Eric Bruckert, Anton F.H. Stalenhoef, Ben P.M. Imholz, Paul N. Durrington, M.D. Trip, Mats Eriksson, Frank L.J. Visseren, Juergen R. Schaefer & John J.P. Kastelein. (2010) Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial. Clinical Therapeutics 32:4, pages 615-625.
Crossref
Crossref
Prasanth N Surampudi, Prathima Nagireddy & Vivian A Fonseca. (2009) Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. Therapy 6:4, pages 475-487.
Crossref
Crossref
Runhua Hou & Anne Carol Goldberg. (2009) Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. Endocrinology and Metabolism Clinics of North America 38:1, pages 79-97.
Crossref
Crossref
Alberto Corsini, Eberhard Windier & Michel Farnier. (2009) Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. European Journal of Cardiovascular Prevention & Rehabilitation 16:1, pages 1-9.
Crossref
Crossref
John R. Guyton & Anne Carol Goldberg. 2009. Clinical Lipidology. Clinical Lipidology
281
287
.
A. S. Wierzbicki. (2008) Muddy waters: more stormy SEAS for ezetimibe. International Journal of Clinical Practice 62:10, pages 1470-1473.
Crossref
Crossref
Susan J. Appel, Natalie A. Floyd & Emily J. Jones. (2007) Reducing Cardiovascular Risk and Managing Dyslipidemia in Women. Nursing for Women's Health 11:6, pages 586-599.
Crossref
Crossref
Harold E Bays & Ronald B Goldberg. (2007) The ‘Forgotten’ Bile Acid Sequestrants: Is Now a Good Time to Remember?. American Journal of Therapeutics 14:6, pages 567-580.
Crossref
Crossref
Dean M. Robinson & Gillian M. Keating. (2012) Colesevelam. American Journal of Cardiovascular Drugs 7:6, pages 471-483.
Crossref
Crossref
Anne Carol Goldberg. (2007) Combination therapy of dyslipidemia. Current Treatment Options in Cardiovascular Medicine 9:4, pages 249-258.
Crossref
Crossref